SS
ANTX icon

SBI Securities’s AN2 Therapeutics ANTX Stock Holding History

SBI Securities’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$973 Hold
201
– – ﹤0.01% 2815
2026
Q1 		$687 Buy
201
+1
+0.5% +$2 ﹤0.01% 2783
2025
Q4 		$228 Hold
200
– – ﹤0.01% 3171
2025
Q3 		$254 Hold
200
– – ﹤0.01% 3239
2025
Q2 		$212 Hold
200
– – ﹤0.01% 3286
2025
Q1 		$272 Hold
200
– – ﹤0.01% 3108
2024
Q4 		$276 Buy
+200
New +$243 ﹤0.01% 3125

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

SBI Securities's ANTX Position: Q2 2026 in Review

SBI Securities held its AN2 Therapeutics (ANTX) position steady in Q2 2026 at 201 shares worth $973. The position accounts for ﹤0.01% of the portfolio, ranked #2815.

SBI Securities first reported a position in ANTX in Q4 2024 and has held it in 7 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • SBI Securities held 201 shares of AN2 Therapeutics worth $973 as of Q2 2026.
  • SBI Securities left its AN2 Therapeutics share count unchanged in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2815 holding.
  • SBI Securities first reported a position in AN2 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.